undamentalytics Newsletter
Sign in

Contineum Therapeutics, Inc. (CTNM) stock

Add to watchlist

Add holding +

NASDAQ: CTNM Nasdaq Biotechnology

Contineum Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 3 selling0 purchases and 31 sales by directors and officers, last 12 monthsInsider trades
  • Funds60 adding, 34 cuttingOf 28 active managers that changed their stake, 10 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 11% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Contineum Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 79% and a beta of 1.4 against the S&P 500.
  • Heavily shorted. 11.1% of the shares available to trade are sold short (2.9 days of average volume to cover).

Latest results

Earnings per share
-$0.40 against an average estimate of -$0.45: beat by 10.8%
Share reaction
+7.7% in the first session after the results on July 30, 2026, against +2.4% for the S&P 500
Next report
November 2, 2026; average EPS estimate -$0.45

Contineum Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.8%
  • 1 week+17.4%
  • 1 month-27.1%
  • This year-16.4%
  • 1 year-13.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
July 30, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results
  3. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Contineum Therapeutics, Inc. valuation models and calculator

No model value for Contineum Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Contineum Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.97 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Contineum Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.70 +22% — 0%
Next −$1.93 −14% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +2.9% on 90 days ago. In the last 30 days, 1 analyst raised Contineum Therapeutics, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Contineum Therapeutics, Inc., last 90 days
−$2.00 −$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.65 Current fiscal year, 60 days ago: −$1.56 Current fiscal year, 30 days ago: −$1.56 Current fiscal year, 7 days ago: −$1.71 Current fiscal year, Now: −$1.70 −$1.70 Next fiscal year, 90 days ago: −$1.81 Next fiscal year, 60 days ago: −$1.82 Next fiscal year, 30 days ago: −$1.80 Next fiscal year, 7 days ago: −$1.92 Next fiscal year, Now: −$1.93 −$1.93

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.65−$1.81
60 days ago −$1.56−$1.82
30 days ago −$1.56−$1.80
7 days ago −$1.71−$1.92
Now −$1.70−$1.93

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.45 −$0.40 +10.8%
Mar 2026 −$0.53 −$0.39 +26.6%
Dec 2025 −$0.39 −$0.49 −26.1%
Sept 2025 −$0.46 −$0.45 +1.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

8 analysts, Oct 2026
Buy675%
Hold225%
Sell00%

Monthly trend

  1. Oct 20261528
  2. Sep 20261618
  3. Aug 20261618
  4. Jul 20261618

Counts of recommendations published by analysts covering Contineum Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
11.1%
of tradable shares
Days to cover
2.9
at average volume
Short interest, 1 month
+50%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.1%
of shares
Employees
51
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20252026 to date
Return
CTNM−22%−16%
Industry peers (median)−5%−27%
S&P 500+18%+11%
Months that ended higher
CTNM50%55%
S&P 50075%46%
Largest fall from a high during the year
CTNM−77%−60%
S&P 500−19%−9%

Worst fall since April 5, 2024: 84% from July 16, 2024 to May 28, 2025. Getting back needed a 540% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$7.08 – $17.57
From 52-week high
−45.6%
vs 50-day average
−23.8%
vs 200-day average
−29.4%
Volatility (1 year)
79%
Beta vs S&P 500
1.39

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 2 down
typical move ±5.8%
After a week
8 up, 2 down
typical move ±7.2%
After a month
6 up, 4 down
typical move ±17.3%
Results releasedNext dayS&P 500 next day5 days21 days
July 30, 2026 +7.7% +2.4% +6.7% +18.6%
May 5, 2026 +5.6% +2.2% −3.5% −12.8%
March 5, 2026 −6.6% −1.9% −6.7% −9.6%
October 30, 2025 +1.0% −0.8% +1.0% +0.8%
August 5, 2025 +9.1% +0.3% +16.4% +89.5%
May 14, 2025 +3.4% +0.6% +1.2% +16.3%
March 6, 2025 +11.0% −1.2% +17.0% −4.9%
November 6, 2024 +11.7% +3.3% +12.8% −11.5%
August 13, 2024 −0.2% +2.0% +1.6% +4.2%
May 16, 2024 +1.2% −0.1% +5.2% +4.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$501M
Institutions reporting
102
Shares held vs prior quarter
0.0%
Positions opened / closed
28 / 15

Top buyers and sellers, Q2 2026: 60 institutions bought and 34 sold ; the biggest buyer was Blackrock, Inc (+1.4M shares) and the biggest seller Baker Bros. Advisors LP (−1.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Montanova Capital, LLC $46.6M 2.8M 9.3% 0.0%
Jupiter Topco LLC $44.8M 2.7M 8.9% —
Blackrock, Inc. $33.8M 2.1M 6.8% ▲ 208.5%
Johnson & Johnson $32.4M 2.0M 6.5% 0.0%
Franklin Resources Inc $30.1M 1.8M 6.0% 0.0%
Balyasny Asset Management L.P. $25M 1.5M 5.0% ▼ 9.7%
Vanguard Capital Management LLC $21.7M 1.3M 4.3% ▲ 8.8%
Perceptive Advisors LLC $20.6M 1.3M 4.1% 0.0%
FMR LLC $17M 1.0M 3.4% ▲ 27.6%
Millennium Management LLC $15.3M 932K 3.1% ▼ 39.3%
Great Point Partners LLC $15.1M 921K 3.0% ▲ 15.2%
Longaeva Partners L.P. $13.3M 813K 2.7% ▲ 11.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Contineum Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $1.9M 31 trades by 3 insiders · 100% under pre-set plans
Net ▼ $1.9M net selling
Insider Date Trade Shares Price Value
Stengone Carmine N. CEO and President September 8, 2026 Sell pre-set plan 2,500 $16.46 $41,150
Stengone Carmine N. CEO and President August 3, 2026 Sell pre-set plan 2,500 $16.01 $40,025
Lorrain Daniel S. Chief Scientific Officer July 9, 2026 Sell pre-set plan 25 $16.00 $400
Stengone Carmine N. CEO and President July 8, 2026 Sell pre-set plan 2,500 $16.00 $40,000
Lorrain Daniel S. Chief Scientific Officer July 8, 2026 Sell pre-set plan 1,015 $16.00 $16,240
Lorrain Daniel S. Chief Scientific Officer July 1, 2026 Sell pre-set plan 5,852 $15.67 $91,701
Lorrain Daniel S. Chief Scientific Officer July 1, 2026 Sell pre-set plan 2,501 $16.24 $40,616
Stengone Carmine N. CEO and President June 30, 2026 Sell pre-set plan 10,000 $16.01 $160,100
Watkins Tim CMO & Head of Development June 30, 2026 Sell pre-set plan 10,833 $16.02 $173,545
Lorrain Daniel S. Chief Scientific Officer June 30, 2026 Sell pre-set plan 28,826 $16.04 $462,369
Lorrain Daniel S. Chief Scientific Officer June 1, 2026 Sell pre-set plan 4,170 $13.16 $54,877
Lorrain Daniel S. Chief Scientific Officer May 1, 2026 Sell pre-set plan 3,870 $13.06 $50,542

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 29, 2026 estimated from the company's past filing pattern, not announced

  • July 30, 2026
  • May 5, 2026
  • March 5, 2026
  • October 30, 2025
  • August 5, 2025
  • May 14, 2025

Recent SEC filings

Data status

When each part of this page on Contineum Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Contineum Therapeutics, Inc. in brief

What does Contineum Therapeutics, Inc. do?
Contineum Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Contineum Therapeutics, Inc.'s stock ticker?
Contineum Therapeutics, Inc. trades under the ticker CTNM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Contineum Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Montanova Capital, LLC, Jupiter Topco LLC and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Contineum Therapeutics, Inc. stock?
Over the last 12 months, Contineum Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 31 sales on Form 4. The insider trading page charts every trade.